INT192341

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 0.85
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (PDGFRB) cytoplasmic membrane-bounded vesicle (PDGFRB) plasma membrane (PDGFRB)
nucleus (PDGFRB) cytoplasm (PDGFRB) signal transducer activity (PDGFRB)
Anatomy Link Frequency
3G3 4
PDGFRB (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 27 94.24 High High
Potency 3 9.84 Low Low
cytokine 5 5.00 Very Low Very Low Very Low
Inflammation 5 5.00 Very Low Very Low Very Low
corticosteroid 4 5.00 Very Low Very Low Very Low
addiction 3 5.00 Very Low Very Low Very Low
Paresthesia 2 5.00 Very Low Very Low Very Low
backache 2 5.00 Very Low Very Low Very Low
peripheral neuropathy 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 49 96.68 Very High Very High Very High
Fibrosis 25 94.24 High High
Cancer 41 80.40 Quite High
Pulmonary Fibrosis 9 69.20 Quite High
Ovarian Cancer 95 61.64 Quite High
Disease 48 43.84 Quite Low
Apoptosis 21 13.84 Low Low
Syndrome 56 13.40 Low Low
Toxicity 90 9.08 Low Low
Neutropenia 26 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Importantly, RTK inhibitors could effectively attenuate this paracrine radiation-induced activation by blocking autophosphorylation of PDGFR and by downregulation of PDGFR expression.
Negative_regulation (downregulation) of Gene_expression (expression) of PDGFR
1) Confidence 0.40 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1458351 Disease Relevance 0.24 Pain Relevance 0.08
Modulation and inhibition of the PDGFR ?
Negative_regulation (inhibition) of Gene_expression (Modulation) of PDGFR
2) Confidence 0.31 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2925350 Disease Relevance 0.10 Pain Relevance 0
A summary of the ongoing trials investigating the combination of PLD with other growth factor receptor inhibitors such as IMC-3G3, an inhibitor of PDGF-R (NCT00913835), panitumumab (an EGF-R blocker) (NCT00861120), and pazopanib (which interferes with VEGF-R1,2,3 kinase, PDGF-R and c-kit oncogene product) (NCT01035658) can be found at the www.clinicaltrials.gov.
Negative_regulation (inhibitor) of Gene_expression (product) of PDGF-R in 3G3
3) Confidence 0.03 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 0.26 Pain Relevance 0
A summary of the ongoing trials investigating the combination of PLD with other growth factor receptor inhibitors such as IMC-3G3, an inhibitor of PDGF-R (NCT00913835), panitumumab (an EGF-R blocker) (NCT00861120), and pazopanib (which interferes with VEGF-R1,2,3 kinase, PDGF-R and c-kit oncogene product) (NCT01035658) can be found at the www.clinicaltrials.gov.
Negative_regulation (inhibitors) of Gene_expression (product) of PDGF-R in 3G3
4) Confidence 0.03 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 0.26 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox